BACKGROUND: Incidence of cutaneous melanoma continues to increase in the Caucasian population worldwide. Approximately 5% of melanoma patients develop additional primary melanoma. This rate is significantly higher than the estimated lifetime risk of an individual for developing the disease (1.4%). These features suggest that a genetic predisposition may underlie multiple primary melanomas (MPMs). Prior studies had identified CDKN2A mutations in a few MPM individuals. The objectives of this study were to determine the frequency of family history of melanoma in MPM cases, to characterize other clinical features including history of other cancer, and to determine the association with functional CDKN2A mutations. METHODS: This study used a case series design. All living patients who had been seen in the Pigmented Lesion Clinic at the University of Pennsylvania and who had more than one primary invasive malignant melanoma or an invasive primary followed by an in situ melanoma were eligible for participation. RESULTS: Individuals with MPM frequently had a family history of melanoma, dysplastic nevi (DN), and/or another cancer including basal cell carcinoma (BCC), and squamous cell carcinoma breast cancer, and a personal history of DN, and basal cell carcinoma. Germline mutations in CDKN2A gene were identified in 8 of 96 MPM cases (8.3%, 95% confidence interval, 6.7-9.9%). CONCLUSIONS: These data indicate that the presence of MPM is associated with a modest incidence of a family history of melanoma, DN, or BCC and a small association with CDKN2A mutations. Therefore, in addition to the MPM index case, other family members can benefit from screening and regular surveillance for melanoma, DN, and BCC. Copyright 2002 American Cancer Society.
BACKGROUND: Incidence of cutaneous melanoma continues to increase in the Caucasian population worldwide. Approximately 5% of melanomapatients develop additional primary melanoma. This rate is significantly higher than the estimated lifetime risk of an individual for developing the disease (1.4%). These features suggest that a genetic predisposition may underlie multiple primary melanomas (MPMs). Prior studies had identified CDKN2A mutations in a few MPM individuals. The objectives of this study were to determine the frequency of family history of melanoma in MPM cases, to characterize other clinical features including history of other cancer, and to determine the association with functional CDKN2A mutations. METHODS: This study used a case series design. All living patients who had been seen in the Pigmented Lesion Clinic at the University of Pennsylvania and who had more than one primary invasive malignant melanoma or an invasive primary followed by an in situ melanoma were eligible for participation. RESULTS: Individuals with MPM frequently had a family history of melanoma, dysplastic nevi (DN), and/or another cancer including basal cell carcinoma (BCC), and squamous cell carcinoma breast cancer, and a personal history of DN, and basal cell carcinoma. Germline mutations in CDKN2A gene were identified in 8 of 96 MPM cases (8.3%, 95% confidence interval, 6.7-9.9%). CONCLUSIONS: These data indicate that the presence of MPM is associated with a modest incidence of a family history of melanoma, DN, or BCC and a small association with CDKN2A mutations. Therefore, in addition to the MPM index case, other family members can benefit from screening and regular surveillance for melanoma, DN, and BCC. Copyright 2002 American Cancer Society.
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Melisa Litchfield; Colin B Begg; Amanda J Hummer; Loraine D Marrett; Beth Theis; Robert C Millikan; Nancy Thomas; Hoda Anton Culver; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Roberto Zanetti; Marianne Berwick Journal: Cancer Causes Control Date: 2007-01-06 Impact factor: 2.506
Authors: Evan S Glazer; Caitlin F Porubsky; Jeffrey D Francis; Jamie Ibanez; Nicholas Castner; Jane L Messina; Amod A Sarnaik; Michael A Harrington; C Wayne Cruse; Vernon K Sondak; Jonathan S Zager Journal: Ann Plast Surg Date: 2017-06 Impact factor: 1.539
Authors: Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong Journal: Ann Surg Oncol Date: 2011-09-13 Impact factor: 5.344
Authors: Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao Journal: J Am Acad Dermatol Date: 2009-10 Impact factor: 11.527